Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

Reports Q4 revenue $2.91B, consensus $2.78B. “2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another ...

Despite "another impressive quarterly revenue beat" on Tuesday and solid guidance, Vertex stock dipped on light profit.

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

Highlights,Increased institutional ownership in Vertex Inc. with notable transactions recorded.,Strong year-over-year revenue ...

Carle Heath is stepping up its specialty care options this month for foot and ankle health at its Eureka hospital.

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

A street sign for Wall Street is seen outside the New York Stock Exchange (NYSE) in Manhattan, New York City, U.S. December 28, 2016. REUTERS/Andrew Kelly/File Photo Wall Street's main indexes ...

The Graph price prediction anticipates a high of $0.419 by the end of 2025. In 2028, it will range between $0.978 and $1.12, with an average price of $1.05. In 2031, it will range between $1.68 and $1 ...

Highlights,Institutional stakeholders demonstrate heightened interest in Waters Corporation with notable activity.,Waters ...